Managing hyperlipidaemia in patients with COVID-19 and during its pandemic: An expert panel position statement from HEART UK

The emergence of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which causes Coronavirus Disease 2019 (COVID-19) has resulted in a worldwide pandemic. SARS-CoV-2 is highly contagious and its severity highly variable. The fatality rate is unpredictable but is amplified by several factors including advancing age, atherosclerotic cardiovascular disease, diabetes mellitus, hypertension and obesity. A large proportion of patients with these conditions are treated with lipid lowering medication and questions regarding the safety of continuing lipid-lowering medication in patients infected with COVID-19 have arisen.

Source: Atherosclerosis - September 13, 2020 Category: Cardiology Authors: Zohaib Iqbal, Jan Hoong Ho, Safwaan Adam, Michael France, Akheel Syed, Dermot Neely, Alan Rees, Rani Khatib, Jaimini Cegla, Christopher Byrne, Nadeem Qureshi, Nigel Capps, Gordon Ferns, Jules Payne, Jonathan Schofield, Kirsty Nicholson, Dev Datta, Alison Tags: Review article Source Type: research